QUIDELORTHO CORP Business Combination, Acquisition Related Costs
QUIDELORTHO CORP (QDEL) reported Business Combination, Acquisition Related Costs of $16.10 million for the 3-month period ending 2025-03-30, per its 10-Q filed 2025-05-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2025-05-08
- QUIDELORTHO CORP business combination, acquisition related costs for the quarter ending 2025-03-30 was $16.10M, a 28.76% decline year-over-year.
- QUIDELORTHO CORP business combination, acquisition related costs for the quarter ending 2024-12-29 was $36.90M, a 11.82% increase year-over-year.
- QUIDELORTHO CORP business combination, acquisition related costs for the quarter ending 2024-09-29 was $36.80M, a 38.87% increase year-over-year.
- QUIDELORTHO CORP business combination, acquisition related costs for the quarter ending 2024-06-30 was $30.90M, a 27.69% increase year-over-year.
- QUIDELORTHO CORP business combination, acquisition related costs for fiscal 2024 was $127.20M, a 12.17% increase from fiscal 2023.
- QUIDELORTHO CORP business combination, acquisition related costs for fiscal 2023 was $113.40M, a 16.62% decline from fiscal 2023.
- QUIDELORTHO CORP business combination, acquisition related costs for fiscal 2023 was $136.00M, a 1316.67% increase from fiscal 2022.
- QUIDELORTHO CORP business combination, acquisition related costs for fiscal 2022 was $9.60M, a 159.46% increase from fiscal 2021.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2025-03-30 | $16.10M 10-Q · filed 2025-05-08 | $53.00M derived: sum of 2 quarters · filed 2025-05-08 | $89.80M derived: sum of 3 quarters · filed 2025-05-08 | $120.70M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-29 | $36.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $73.70M derived: sum of 2 quarters · filed 2025-02-27 | $104.60M derived: sum of 3 quarters · filed 2025-02-27 | $127.20M 10-K · filed 2025-02-27 |
| 2024-09-29 | $36.80M 10-Q · filed 2024-11-08 | $67.70M derived: sum of 2 quarters · filed 2024-11-08 | $90.30M 10-Q · filed 2024-11-08 | $123.30M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-06-30 | $30.90M 10-Q · filed 2024-08-01 | $53.50M 10-Q · filed 2024-08-01 | $86.50M derived: sum of 3 quarters · filed 2025-05-08 | $113.00M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-03-31 | $22.60M 10-Q · filed 2025-05-08 | $55.60M derived: sum of 2 quarters · filed 2025-05-08 | $82.10M derived: sum of 3 quarters · filed 2025-05-08 | $106.30M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $59.50M derived: sum of 2 quarters · filed 2025-02-27 | $83.70M derived: sum of 3 quarters · filed 2025-02-27 | $113.40M 10-K · filed 2025-02-27 |
| 2023-10-01 | $26.50M 10-Q · filed 2024-11-08 | $50.70M derived: sum of 2 quarters · filed 2024-11-08 | $80.40M 10-Q · filed 2024-11-08 | $106.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | $24.20M 10-Q · filed 2024-08-01 | $53.90M 10-Q · filed 2024-08-01 | $80.30M derived: sum of 3 quarters · filed 2025-02-27 | $106.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | $29.70M 10-Q · filed 2024-05-09 | $56.10M derived: sum of 2 quarters · filed 2025-02-27 | $82.50M derived: sum of 3 quarters · filed 2025-02-27 | $162.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-01-01 | $26.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $52.80M derived: sum of 2 quarters · filed 2025-02-27 | $133.00M derived: sum of 3 quarters · filed 2025-02-27 | $136.00M 10-K · filed 2025-02-27 |
| 2022-10-02 | $26.40M 10-Q · filed 2023-11-02 | $106.60M derived: sum of 2 quarters · filed 2023-11-02 | $109.60M 10-Q · filed 2023-11-02 | $117.40M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-07-03 | $80.20M 10-Q · filed 2023-08-09 | $83.20M 10-Q · filed 2023-08-09 | $91.00M derived: sum of 3 quarters · filed 2024-08-01 | $91.00M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-04-03 | $3.00M 10-Q · filed 2023-05-04 | $10.80M derived: sum of 2 quarters · filed 2024-08-01 | $10.80M derived: sum of 3 quarters · filed 2024-08-01 | $11.90M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-01-02 | $7.80M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01 | $7.80M derived: sum of 2 quarters · filed 2024-08-01 | $8.90M derived: sum of 3 quarters · filed 2024-08-01 | $9.60M 10-K/A · filed 2024-08-01 |
| 2021-10-03 | $0.00 10-Q · filed 2022-11-04 | $1.10M derived: sum of 2 quarters · filed 2022-11-04 | $1.80M 10-Q · filed 2022-11-04 | |
| 2021-07-04 | $1.10M 10-Q · filed 2022-08-05 | $1.80M 10-Q · filed 2022-08-05 | ||
| 2021-01-03 | $3.70M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |